Akebia Therapeutics Inc. | Ownership
Companies that own Akebia Therapeutics Inc.
Nantahala Capital Management LLC
4,523,111
7.93%
1,136,968
2.67%
06/30/2018
BlackRock Fund Advisors
4,184,155
7.34%
542,634
0%
06/30/2018
The Vanguard Group, Inc.
2,478,999
4.34%
209,901
0%
06/30/2018
Perceptive Advisors LLC
2,215,400
3.88%
-247,000
0.41%
06/30/2018
Carillon Tower Advisers, Inc.
2,060,804
3.61%
0
0.12%
06/30/2018
SSgA Funds Management, Inc.
1,930,404
3.38%
430,191
0%
06/30/2018
Renaissance Technologies LLC
1,874,600
3.29%
-644,500
0.02%
06/30/2018
Morgan Stanley Smith Barney LLC (Private Banking)
1,280,395
2.25%
273,199
0.01%
06/30/2018
Fidelity Management & Research Co.
814,155
1.43%
0
0%
06/30/2018
Citadel Advisors LLC
620,336
1.09%
391,022
0.01%
06/30/2018
| Address |
245 First Street
Cambridge Massachusetts 02142
United States
|
|
Employees
|
- |
| Website |
http://www.akebia.com |
| Updated |
07/08/2019 |
| Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for hypoxia-inducible factor. It also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. It offers vadadustat, which is an oral therapy for the treatment of anemia due to chronic kidney disease. |
